BIOQUEST CORP. (BQST) earnings per share
| Period | End | Diluted | Filed |
|---|---|---|---|
| FY 2022 | 2022-04-30 | — | 2022-08-15 |
| FY 2021 | 2021-04-30 | — | 2021-08-13 |
| Period | End | Diluted | Filed |
|---|---|---|---|
| Q1 2023 | 2022-07-31 | — | 2022-09-12 |
| Q4 2022 | 2022-04-30 | — | 2022-08-15 |
| Q3 2022 | 2022-01-31 | $0.00 | 2022-05-27 |
| Q2 2022 | 2021-10-31 | — | 2022-05-16 |
| Q1 2022 | 2021-07-31 | — | 2022-04-29 |
| Q4 2021 | 2021-04-30 | — | 2021-08-13 |
| Q3 2021 | 2021-01-31 | -$0.08 | 2021-06-15 |
| Q2 2021 | 2020-10-31 | — | 2020-12-14 |
| Q2 2021 | 2020-07-31 | — | 2020-12-14 |
| Q3 2015 | 2015-01-31 | — | 2015-03-17 |
| Q2 2015 | 2014-10-31 | — | 2014-12-15 |
| Q3 2014 | 2014-01-31 | — | 2014-03-25 |
| Q2 2014 | 2013-10-31 | — | 2013-12-17 |
| Period | End | FCF / Share | Filed |
|---|---|---|---|
| Q3 2015 | 2015-01-31 | -$22.20 | 2015-03-17 |
| Q2 2015 | 2014-10-31 | -$12.60 | 2014-12-15 |
| Q3 2014 | 2014-01-31 | -$0.20 | 2014-03-25 |
| Q2 2014 | 2013-10-31 | -$0.20 | 2013-12-17 |
Methodology
Annual rows come from the filer's 10-K and Q1–Q3 rows from
the matching 10-Q; Q4 is derived as full-year minus nine-month
YTD because XBRL doesn't tag Q4 as its own period.
EPS Basic and EPS Diluted
are reported directly by the filer.
FCF / Share is computed as
(Operating Cash Flow − Capital Expenditures) ÷ Diluted
Shares Outstanding. When SEC companyfacts omits the
direct diluted-share concept for an older period, we
imply it from NetIncomeLoss ÷ EarningsPerShareDiluted.
For financial filers whose operating cash flow includes
customer-fund activity (e.g. Mercado Pago deposits),
FCF may materially exceed net income because the fintech
float is recorded inside OCF under US GAAP.
Per-share values are split-adjusted
to the current share count (2 split
s since
2014).
For the exact XBRL concepts and formulas, see the methodology reference for EPS, FCF per share, the Q4 derivation, and split adjustment.
BQST CIK 0001568628 Source: EDGAR filings · all facts